Search

Displaying results 6291 - 6300 of 10000 in total
  1. Drug

    Ichorcumab

    go.drugbank.com/drugs/DB18930
    Investigational

    Ichorcumab is under investigation in clinical trial NCT03251482 (A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee

  2. Drug

    Fulacimstat

    go.drugbank.com/drugs/DB15085
    Investigational

    Fulacimstat is under investigation in clinical trial NCT02452515 (A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With

  3. Drug

    MEM 1003

    go.drugbank.com/drugs/DB05547
    Investigational

    MEM 10003 was under investigation in clinical trial NCT00257673 (Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease) for the treatment of Alzheimer's Disease

  4. Drug

    Indoramin

    go.drugbank.com/drugs/DB08950
    ApprovedWithdrawn

    Indoramin is a discontinued piperidine antiadrenergic drug with the trade names Baratol and Doralese.

    Categories: Adrenergic alpha-1 Receptor Antagonists
  5. Drug

    NB-001

    go.drugbank.com/drugs/DB12716
    Investigational

    NB-001 has been investigated for the treatment of Recurrent Herpes Labialis.

  6. Drug

    Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15740
    Investigational

    Human olfactory mucosa-derived mesenchymal stem cells (OM-MSCs) reside in an accessible location of the nasal cavity and have properties of multipotency and high proliferation, which contributes to high … In humans, OM-MSCs are derived from the olfactory mucosa which is collected in vivo through rhinoscopy techniques and nasal forceps.

  7. Drug

    Tetrathiomolybdate

    go.drugbank.com/drugs/DB05088
    Investigational

    It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the availability of free copper in the body. … COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease.

  8. Drug

    V590

    go.drugbank.com/drugs/DB16437
    Experimental

    Merck is currently underway to begin Phase I trials for the vaccine through intramuscular administration (NCT04569786). … The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578].

  9. Drug

    Mirfentanil

    go.drugbank.com/drugs/DB09175
    Experimental

    Mirfentanil is a derivative of fentanyl that presents high selectivity for the mu opioid receptor. … to discriminate morphine from naloxone.

  10. Drug

    Loprazolam

    go.drugbank.com/drugs/DB13643
    Experimental

    It is a positive modulator of GABA-A receptor that enhances the inhibitory neurotransmission. It is not an FDA-approved drug. … Loprazolam is recommended as a short-term therapy only, due to adverse events associated with the drug including dependence and withdrawal symptoms.